Most frequent TEAEs occurring in ≥10% of patients by preferred term (safety population)
ADVERSE EVENT
TEAEs are defined as any adverse event that occurs after administration of the first dose of study treatment through 28 days after the last dose of study treatment, or until the start of subsequent antineoplastic therapy. Abbreviations: ALT: alanine aminotransferase; CPK: creatine phosphokinase.